Shares of Hikma Pharmaceuticals PLC HIK inched down 0.35% to £19.82 Friday, on what proved to be an all-around favorable ...
The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...
The global dyspnea treatment market, valued at USD 6.31 billion in 2023, is poised for remarkable growth, with projections ...
Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...
Shares of Hikma Pharmaceuticals PLC HIK inched up 0.05% to £19.89 Tuesday, on what proved to be an all-around great trading ...
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...
The FDA granted the approval of generic liraglutide injection to Hikma Pharmaceuticals USA Inc. Please contact the ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
FDA approves Hikma Pharmaceuticals' generic version of Victoza, a once-daily GLP-1 injection for Type 2 diabetes. Other drugmakers also entering the market.
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback